Valuation: Scholar Rock Holding Corporation

Market Cap 5.72B 5.13B 4.69B 4.28B 8.06B 537B 8.31B 56.48B 22.52B 287B 21.46B 21B 905B P/E 2026 *
-14.3x
P/E 2027 * -17.8x
Enterprise Value 5.4B 4.84B 4.43B 4.04B 7.61B 508B 7.85B 53.35B 21.27B 271B 20.27B 19.83B 855B EV / Sales 2026 *
952x
EV / Sales 2027 * 37.4x
Free-Float
99.27%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Scholar Rock Holding Corporation

1 day+3.16%
1 week+6.92%
Current month+6.92%
1 month+11.23%
3 months-11.30%
6 months-3.00%
Current year+6.56%
1 week 43.13
Extreme 43.13
47.9
1 month 38.69
Extreme 38.69
47.9
Current year 38.69
Extreme 38.69
61.76
1 year 28.79
Extreme 28.79
61.76
3 years 6.76
Extreme 6.76
61.76
5 years 4.32
Extreme 4.325
61.76
10 years 4.32
Extreme 4.325
70
Manager TitleAgeSince
Chief Executive Officer 59 2025-04-26
Director of Finance/CFO 62 2025-04-26
Chief Operating Officer 58 2025-04-26
Director TitleAgeSince
Chairman 59 2017-06-30
Director/Board Member 53 2014-07-31
Director/Board Member 78 2016-09-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/24/26 Don

Chief Operating Officer

-48,034 0.0394%
9/21/26 Don

Chief Executive Officer

-36,652 0.0301%
7/1/26 Sell

Director

-2,544 0.0022%
Change 5-day change 1-year change 3-year change Capi.($)
+3.16%+6.92%+62.14%+292.80% 5.72B
-4.83%+3.51%+55.00%+62.02% 66.7B
+4.39%+8.62%+14.28%+84.93% 56.88B
+0.99%+3.49%+25.62%+97.76% 56.53B
+5.09%+9.89%+27.19%+103.27% 46.49B
+2.62%+1.68%+29.16%+36.08% 44.8B
+8.24%+0.51%+215.16%+807.84% 41.59B
-1.86%+10.13%+28.14%+53.61% 35.35B
+3.71%-0.97%+95.25%+66.83% 33.29B
+5.19%+1.62%-39.69%+381.71% 25.1B
Average +2.68%+3.08%+51.22%+198.68% 41.24B
Weighted average by Cap. +2.16%+3.13%+50.85%+169.44%

Financials

2026 *2027 *
Net sales 5.67M 5.09M 4.65M 4.25M 8M 533M 8.25M 56.06M 22.36M 285M 21.3M 20.84M 898M 142M 127M 116M 106M 200M 13.32B 206M 1.4B 558M 7.11B 532M 520M 22.44B
Net income -427M -383M -350M -320M -602M -40.14B -621M -4.22B -1.68B -21.42B -1.6B -1.57B -67.61B -358M -321M -294M -268M -505M -33.67B -521M -3.54B -1.41B -17.97B -1.34B -1.32B -56.72B
Net Debt -316M -284M -259M -237M -446M -29.75B -460M -3.13B -1.25B -15.87B -1.19B -1.16B -50.11B -410M -368M -336M -307M -579M -38.58B -597M -4.05B -1.62B -20.58B -1.54B -1.51B -64.98B
Projected Income Statement - Annual - Scholar Rock Holding Corporation
Logo Scholar Rock Holding Corporation
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
Employees
289
Date Price Change Volume
26-11-06 US$46.94 +3.16% 2,096,407
26-11-05 US$45.50 -1.28% 1,455,726
26-11-04 US$46.09 +4.80% 1,710,475
26-11-03 US$43.98 +2.49% 676,834
26-11-02 US$42.91 -2.26% 932,047
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Scholar Rock Holding Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
46.94USD
Average target price
70.44USD
Spread / Average Target
+50.06%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Scholar Rock Holding Corporation
  1. Stock Market
  2. Stocks
  3. SRRK Stock